Fulcrum therapeutics announced results of phase 1 clinical trial of losmapimod in fshd

Fulcrum therapeutics announced results of phase 1 clinical trial of losmapimod in fshd.fulcrum therapeutics-preliminary results from phase 1 clinical trial of losmapimod in patients with fshd indicate losmapimod was generally well tolerated.fulcrum therapeutics- primary objective of trial was to investigate safety and tolerability of losmapimod in healthy volunteers and in fshd patients.fulcrum therapeutics- losmapimod was well tolerated with no serious adverse events (saes) reported.
FULC Ratings Summary
FULC Quant Ranking